Nuvalent, Inc. · 1 day ago
Senior Oncology Account Manager (Sales): San Diego, CA
Nuvalent is an exciting early-stage company focused on creating selective medicines for cancer patients. The Senior Oncology Account Manager will drive sales objectives by providing healthcare professionals with information about Nuvalent's products and implementing marketing strategies effectively.
BiotechnologyLife ScienceTherapeutics
Responsibilities
Achieve the assigned sales objective for the territory
Attain the designated goals for calls on appropriate healthcare professionals to communicate balanced, accurate, and complete information on Nuvalent’s FDA approved products
Develop and implement a territory business plan to meet customer needs and achieve goals
Navigate through complex external/customer organizational structures, including hospitals, integrated delivery networks (IDNs), group purchasing organizations (GPOs), and healthcare communities, while aligning with cross-functional commercial partners. Be passionate and motivated through headwinds, driving results in the face of adversity
Demonstrate adherence of administrative requirements, including budget management, expense reports management, CRM call reporting and synchronization, etc., within timelines and company guidelines
Demonstrate a deep understanding of healthcare professionals (HCP) and account needs, effectively utilizing this knowledge to strategically promote and expand the use of assigned products
Operate the territory within the assigned expense budget and demonstrate fiscal responsibility
Comply with all federal, state, and local laws, regulations, and guidelines, including but not limited to the PhRMA Code on Interactions with Healthcare Professionals, as well as complying with all Nuvalent standards and policies relating to all job activities
Successfully complete training and participation in ongoing updates, including but not limited to product knowledge, disease state, market, selling skills, and compliance
Assist in the identification and resolution of issues and opportunities while communicating proactively with marketing and sales management. Be disciplined but also willing to challenge norms and processes for continuous improvement. Develop and consistently demonstrate an expert understanding of HCP and Account needs to expand the use of the assigned product appropriately
Operate with a strong business owner mentality, taking full accountability for territory outcomes
Candidates must demonstrate rare / ultra rare experience and a willingness to navigate highly specialized, challenging markets. Partner seamlessly with Market Access, Medical Affairs (MSLs), Precision Engagement Managers, and Commercial leadership, collaborating cross-functionally, to deliver integrated customer support
Utilizing competitive intelligence, identifies and reports shifts in competitor activity, market trends, and customers’ needs to inform strategy and use the data deliberately in all aspects of account and territory management
Qualification
Required
Undergraduate degree is required, ideally in business, marketing, healthcare, life science areas of concentration
9+ years of successful pharmaceutical/biotech sales experience with 3+ in the oncology/hematology and/or rare disease markets, preferably with oral therapeutic selling experience
Excellent written and oral communication skills
Strong computer skills, notably MS Word, MS Excel, and MS PowerPoint
Periodic overnight travel will be needed for the management of large territories
Occasional evenings and weekend work may be needed for conferences
Benefits
Medical, dental, and vision insurance
401 (k) retirement savings plan
Generous paid time off (including a summer and winter company shutdown)
Company
Nuvalent, Inc.
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets.
Funding
Current Stage
Public CompanyTotal Funding
$1.82BKey Investors
Bain Capital Life SciencesDeerfield
2025-11-18Post Ipo Secondary· $500M
2024-09-16Post Ipo Equity· $575M
2023-10-16Post Ipo Equity· $300M
Recent News
MarketScreener
2025-12-16
Company data provided by crunchbase